Vertex Pharmaceuticals– tag –
-
Vertex’s CASGEVY Gene Therapy Expands FDA Approval to Pediatric Patients 2+ for Sickle Cell and Beta-Thalassemia; Umoja’s In Vivo CAR-T for Solid Tumors Enters Clinic
BioInsights USA Overview July 2026 marked significant progress in gene and cell therapy access, with Vertex Pharmaceuticals' CASGEVY receiving expanded FDA approval for pediatric patients aged 2 and older with sickle cell disease and tra... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c... -
From Noise to Novel 3D Molecules: Diffusion Models Transform Drug Design AI
Google Cloud Vertex AI Search USA Overview Diffusion models, a breakthrough AI methodology successful in image generation, are now being applied to molecular structure generation for drug design. These models generate new molecules by pr... -
Large Models Reshape Chemistry: Generative AI Drives Novel Molecular Design in Drug Discovery
Google Cloud Vertex AI Search USA Overview Generative AI is fundamentally transforming drug chemistry by creating novel molecular structures rather than merely screening existing ones. These large machine learning models learn patterns o... -
Generative AI Accelerates Drug Discovery: Reshaping Molecular Design and Translational Decision-Making
Google Cloud Vertex AI Search USA Overview Generative AI is poised to revolutionize the entire drug discovery pipeline, from initial molecular design and chemical space exploration to ADMET prediction and crucial translational decision-m... -
Global Pluripotent Stem Cell Therapies Progress to 115 Clinical Trials with Over 1,200 Patients, Demonstrating Strong Safety Profile
Vertex AI Search Global Overview Global clinical trials involving pluripotent stem cell therapies have significantly advanced, with 115 trials treating over 1,200 patients by December 2024, reporting no major safety concerns. This progre... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
FDA Approves Casgevy for Expanded Use in Pediatric Patients Aged 2 and Older with Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Seeking Alpha USA Overview Crispr Therapeutics and Vertex Pharmaceuticals announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) to include pediatric patients aged 2 and older with sickle c... -
Dual-Target CAR T Therapy for Glioblastoma Drives Broad Immune Activation, NK Cell Response Correlates with Long-Term Survival in Penn Medicine Study
Vertex AI Search USA Overview Researchers at the Perelman School of Medicine and Abramson Cancer Center discovered that direct intra-cerebrospinal fluid (CSF) delivery of a dual-target CAR T-cell therapy induces a broad immune response i... -
MSC-Derived Exosomes Emerge as Promising Cell-Free Regenerative Therapies, Driving Active Research in Arthritis, Chronic Wounds, and Inflammatory Diseases
Vertex AI Search USA Overview Mesenchymal Stem Cell (MSC)-derived exosomes are garnering significant attention in regenerative medicine as a cell-free therapeutic alternative, capable of delivering MSCs' potent regenerative and immunomod...
